Safety, tolerability, and preliminary efficacy of ascending doses of Human Allogeneic Liver-derived Progenitor Cells (HepaStem®) in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH)-MedSci.cn

Safety, tolerability, and preliminary efficacy of ascending doses of Human Allogeneic Liver-derived Progenitor Cells (HepaStem®) in patients with cirrhotic and pre-cirrhotic non-alcoholic steatohepatitis (NASH)

Francque, S; Moreno, C; Saliba, F; Vargas, V; Ibañez, L; Soriano, G; Genov, J; Katzarov, K; Janczewska, E; Iliescu, EL; Geerts, A; Gordillo, N; Vainilovich, Y; Najimi, M; Barthel, V; Lin, F; Sokal, E

JOURNAL OF HEPATOLOGY, 2023; 78 (): S807

科室
- - 订阅+
  - 更多科室
工具
服务